Skip to main content

25-09-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

Read the transcript

Image Credits